Skip to content
Beacon

TBXUDirexion Daily Biotech Top 5 Bull 2X ETF

Take a betNewRanked #744 of 775 in this goal

Seeks daily investment results of 200% of the daily performance of the NYSE Biotechnology Index.

By Direxion Funds · Launched 2025

Annual Cost

0.98%

#4,853 of 5,562 · expensive

Fund Size

$3M

#5,239 of 5,562 · small

Return (1Y)Goal

N/A

Track Record

9 months

#4,813 of 5,562 · young

Performance

Total-return NAV · USD
Growth of $10,000
$11,340+13.4%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Strategy

Leveraged

Sector

Health care

Index tracked

NYSE Biotechnology Index

What it actually holds

By weight

Concentration

Top 10 holdings = 99.9% of fundconcentrated

DREYFUS GOVERNMENT CASH MANAGE
22.3%
Regeneron Pharmaceuticals, Inc.
12.9%
Amgen Inc.
12.0%
Vertex Pharmaceuticals Incorporated
12.0%
Gilead Sciences Inc.
11.6%
Alnylam Pharmaceuticals Inc.
10.9%
GOLDMAN FINANCIAL
10.7%
N/A
4.0%
N/A
3.7%
GOLDMAN SACHS LIQ ES FD A
0.0%

Asset allocation

Cash
59.3%
Stocks
40.7%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
N/A
Max drawdown
-26.5%Moderate

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange
NYSE Arca

Full fund details

Objective
Seeks daily investment results of 200% of the daily performance of the NYSE Biotechnology Index.
Strategy
Invests primarily in the top five securities of the NYSE Biotechnology Index, providing 2x daily leveraged exposure. The Index is equal-weighted and rebalanced quarterly, focusing on U.S.-listed biotech companies.
Inception date
September 30, 2025
Fund family
Direxion Funds

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged
Warning

Leveraged ETF — not a long-term hold

This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.

Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)

Why we flagged this: strategy=leveraged + leveraged_name_or_strategy

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed TBXU. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-19